Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
BACKGROUND
As aminoglycosides show concentration-dependent killing, once-daily aminoglycoside (ODA) regimens have been instituted. Data on experience with ODA regimens in critically ill patients are limited.


OBJECTIVE
1) To evaluate the ODA-program in critically ill patients; 2) to describe the pharmacokinetics of aminoglycosides (gentamicin and tobramycin); and 3) to assess the incidence of nephrotoxicity associated with an ODA regimen in this specific of group patients.


METHODS
A prospective, descriptive study.


METHODS
Eighteen-bed surgical and 12-bed medical intensive care unit in a referral centre.


METHODS
Eighty-nine critically ill patients with a suspected or confirmed infection for which gentamicin or tobramycin was indicated and a creatinine clearance > 30 ml/min were monitored. One hundred and nine pharmacokinetic profiles were gathered.


METHODS
A first dose of 7 mg/kg/24 h of gentamicin or tobramycin was given to every patient independent of renal function. Subsequent doses were chosen on the basis of the pharmacokinetic results of the first dose.


METHODS
Serum samples were collected 1 h and 6 h after start of the aminoglycoside infusion. All samples were assayed by using immunofluorescence. Pharmacokinetic parameters were estimated using a one-compartment model.


RESULTS
The volume of distribution of aminoglycosides was significantly higher in critical ill patients with septic shock than in those without. Consequently, the maximum concentration reached was significantly lower in patients with septic shock. In P. aeruginosa infections the mean (SD) estimated Cmax/MIC ratio was 10.3 (3.3). In n = 17 (49%) of the patients treated > 24 h ( n = 35), a dose adjustment or lengthening of interval was necessary. The recommended dosing interval based on the Hartford Hospital nomogram and one-serum concentration at 6 h was correct in only 62% of all cases. Signs of renal impairment occurred in n = 12 (14%) of the patients; in all survivors renal function recovered completely and no haemofiltration was needed.


CONCLUSIONS
An ODA-regimen of 7 mg/kg produced Cmax/MIC ratios > 10 in the majority of critically ill patients in our population. Septic shock and renal dysfunction caused an aberrant pharmacokinetic profile of aminoglycosides in these patients. Therefore, individual therapeutic drug monitoring is warranted. Signs of renal impairment were common in the presence of shock, but appeared to be reversible.
Dept. of Surgical Intensive Care, Erasmus MC Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. gyssens@bacl.azr.nl
S E
SE
Buijk
J W
JW
Mouton
I C
IC
Gyssens
H A
HA
Verbrugh
H A
HA
Bruining
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D003401:Creatine / Q000097:blood; D003422:Critical Care / Q000379:methods*; D004334:Drug Administration Schedule; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D012772:Shock, Septic / Q000150:complications; D014031:Tobramycin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D003401:Creatine; D014031:Tobramycin